17,261 trials
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
Atrial Fibrillation
Primary: Maximum QTcF — 461; 427 ms
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 26 participants
Carcinoma, Non-Small-Cell Lung
Primary: Time to Progression — 3.1 Months
Multiple Sclerosis
Primary: Fatigue Severity Scale — 5.5; 5.5 units on a scale
Stress
Primary: Stress Levels After 4 Sessions (2nd Evaluation) — 49.68; 54.69; 54.00 units on a scale — p=0.352
Essential Tremor
Primary: Modified FTM(Fahn-Tolosa-Marin) Essentials Tremor Rating Scale, Sum of All Essential Rating Tremor Scales Including Voice Tremor — 13.4; 10.8; 13.0 Points — p=0.013
Multiple Myeloma
Primary: Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma — 0 participants
Interstitial Cystitis
Primary: Number Subjects at Least "Moderately Improved" for Each Treatment Group in Patient Reported Global Response Assessment (GRA) — 31; 26; 30 participants
Multiple Myeloma · Lymphoma
Primary: Average Overall Survival Time — 3 years
Multiple Myeloma
Primary: Progression-free Survival (PFS) — 5.1; 6.2 months — p=0.2804
HIV Infections
Primary: Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping…
Transposition of Great Vessels · Congenital Heart Disease
Primary: Maximum Decline in Measured Cardiac Output — 0.68; 0.29 L/min/m2
Acute Lymphoblastic Leukemia
Primary: MTD of VSLI — 2.25 mg/m2
Factor XIII Deficiency
Primary: Peak FXIII Concentration at Steady State — 0.9 Units/mL